Even with increasingly effective targeted therapies for ALK+ metastatic non-small cell lung cancer (mNSCLC), unanswered questions remain, especially when a patient's disease progresses or treatment becomes difficult to tolerate. In this program, Dr. Angel Qin looks beyond current care strategies to consider where the field is headed, from overcoming resistance to investigating entirely different ways of extending disease control. Dr. Qin is a Clinical Associate Professor of Internal Medicine at the University of Michigan Medical School.
Podden och tillhörande omslagsbild på den här sidan tillhör
ReachMD. Innehållet i podden är skapat av ReachMD och inte av,
eller tillsammans med, Poddtoppen.
